Drug Trial Radar · NCT03670810
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Last checked: Nov 20, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,633
Actual
Start
Jun 24, 2019
Primary completion
Jun 12, 2020
Study completion Jul 8, 2021
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
Conditions
- Migraine
Interventions
LasmiditanDrug
Administered orally.
PlaceboDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants That Are Pain Free 2 Hours Postdose During the First AttackTime frame: 2 Hours Postdose
- Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 AttacksTime frame: 2 Hours Postdose
Locations
141 sites in 17 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services LLC
Huntsville, Alabama
Barrow Neurological Institute
Phoenix, Arizona
UCSD Altman Clinical & Translational Research Institute (ACTRI)
La Jolla, California
Colorado Neurological Institute
Englewood, Colorado
Georgetown University Hospital
Washington D.C., District of Columbia
George Washington University Medical Center
Washington D.C., District of Columbia
Diamond Headache Clinic
Chicago, Illinois
Ochsner Medical Center - North Shore
Covington, Louisiana
StudyMetrix Research, LLC
City of Saint Peters, Missouri
Nevada Headache Institute
Las Vegas, Nevada
Dent Neurological Institute
Amherst, New York
Island Neuro Associates,PC
Plainview, New York
Montefiore Headache Center
The Bronx, New York
Northwest Clinical Research Center
Bellevue, Washington
Christian-Doppler-Klinik
Salzburg, Austria
AKH
Vienna, Austria
Universitätsklinik Innsbruck
Innsbruck, Tyrol, Austria
KH der Barmherzigen Schwestern Linz BetriebsGesmbH
Linz, Upper Austria, Austria
Algemeen Ziekenhuis St Jan Brugge
Bruges, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
CHC MontLégia
Liège, Belgium
Valdor - ISOSL CCV - Clinique des céphalées du Valdor - Neurology
Liège, Belgium
Jessa Ziekenhuis
Hasselt, Limburg, Belgium
Baotou Central Hospital
Baotou, China
Peking Union Medical College Hospital
Beijing, China
Chinese PLA General Hospital
Beijing, China
The First Affiliated Hospital of Harbin Medical University
Harbin, China
Tianjin Medical University General Hospital
Tianjin, China
Beijing Tiantan Hospital Affiliated to Capital Medical Univ
Beijing, Beijing Municipality, China
Xuanwu Hospital-Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
Hebei General Hospital
Shijiazhuang, Hebei, China
First hospital affiliated to Zhengzhou University
Zhengzhou, Henan, China
Wuhan Union (Xiehe) Hospital
Wuhan, Hubei, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
The First Affliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.